BACKGROUND Recent circumstantial evidence suggests that an increasing number of Iranian patients with cutaneous leishmaniasis are unresponsive to meglumine antimoniate (Glucantime), the first line of treatment in Iran. This study was designed to determine whether the clinical responses (healing, or non-healing) were correlated with the susceptibility of Leishmania parasites to Glucantime. MET...

A case of a pediatric patient with a recurrent single lesion, four months after finishing treatment for seven lesions of cutaneous leishmaniasis with intramuscular meglumine antimoniate. Once the recurrence was confirmed by direct visualization of amastigotes, the decision taken was to repeat treatment with 1 cc of intralesional meglumine antimoniate, with a uniform distribution inside the lesi...

A 27 years old female patient was diagnosed with cutaneous leishmaniasis histopathologically and received intramuscular meglumine antimoniate therapy at a dose of 20 mg/kg/day for consecutive 20 days. The base-line pretreatment complete blood count, hepatic transaminases, lipase, amylase, beta-hCG level and electrocardiogram were within normal limits. Following to the treatment-free two weeks a...

This study aims to evaluate the in vitro and in vivo antileishmanial activities of Pistacia vera essential oil and compare their efficacy with a reference drug, meglumine antimoniate (Glucantime®). This essential oil (0-100 µg/mL) was evaluated in vitro against the intracellular amastigote forms of Leishmania tropica (MHOM/IR/2002/Mash2) and then tested on cutaneous leishmaniasis of male BALB/c...

BACKGROUND & OBJECTIVES Pentavalent antimony compounds are the first line of drugs in the treatment of cutaneous leishmaniasis. However, because of their potential toxic effects, many investigations are performed to find an effective and safe treatment for cutaneous leishmaniasis patients. Our objective in this investigation was to compare the effect of oral omeprazole and low dose systemic meg...

Background and objective: Different local and systemic modalities are suggested in the treatment of cutaneous leishmaniasis, but the pentavalent antimony compounds are still considered as the first line of treatment. Regarding to increase in clinical drug resistance and adverse effects, efforts to find a more effective and safer drug is continuing. The objective of this study was to compa...

Visceral leishmaniasis (VL) affects over 500,000 people worldwide each year. The disease occurs in the Mediterranean basin, Central and South America and is caused by Leishmania infantum (syn L. chagasi). VL is an endemic disease in Colombia, particularly along the Caribbean coast and the Magdalena River Valley and 90% of VL cases occur in children under the age of five. The first line of treat...

BACKGROUND To evaluate immunotherapy against canine visceral leishmaniasis, Leishmania major antigen and heat-killed Mycobacterium vaccae (SRL172) were used as stimulators of immune defense mechanisms and the results were compared with standard chemotherapy meglumine antimoniate. METHODS Nineteen mongrel dogs aging 1-3 years old were used in this experiment. Infection was carried out in 15 ou...